• 1.成都軍區(qū)總醫(yī)院全軍普通外科中心(成都610083);;
  • 2.成都軍區(qū)總醫(yī)院病理科;

目的研究肝癌組織中survivin蛋白的表達(dá)及其與肝癌細(xì)胞增殖及預(yù)后的關(guān)系。方法應(yīng)用免疫組織化學(xué)染色對48例原發(fā)性肝癌組織中survivin蛋白與增殖細(xì)胞核抗原(PCNA)的表達(dá)情況進(jìn)行檢測，并結(jié)合臨床預(yù)后進(jìn)行分析。結(jié)果48例肝癌組織中survivin蛋白表達(dá)陽性率為64.6%； survivin蛋白表達(dá)陽性者肝癌細(xì)胞增殖指數(shù)顯著高于表達(dá)陰性者(P=0.007)； survivin蛋白表達(dá)陰性患者與表達(dá)陽性患者比較，1年生存率差異無顯著性意義，但3年生存率前者顯著高于后者(P=0.011)。結(jié)論survivin蛋白對促進(jìn)肝癌細(xì)胞快速增殖具有重要作用，survivin蛋白的表達(dá)可以作為預(yù)后不良的重要指標(biāo)，也可能成為治療肝癌的重要的新靶點。

引用本文： 田伏洲,陳玉瓊,陳濤,尹致良. survivin蛋白在人肝癌組織中的表達(dá)及其與細(xì)胞增殖及預(yù)后的關(guān)系. 中國普外基礎(chǔ)與臨床雜志, 2003, 10(2): 131-133. doi: 復(fù)制

1. 李連第，張思維，魯鳳珠，等. 中國惡性腫瘤死亡譜及分類構(gòu)成研究 [J]. 中華腫瘤雜志， 1997； 19（5）∶323.
2. GraslKraupp B, RuttkayNedecky B, Mullauer L, et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression [J]. Hepatology， 1997； 25(4)∶906.
3. Terada T, Nakanuma Y. Expression of apoptosis, proliferation cell nuclear antigen, and apoptosisrelated antigen (bcl2, cmyc, Fas, Lewisy, and p53) in human cholangiocarcinomas and hepatocellular carcinomas [J]. Pathol Int，1996； 46(10)∶764.
4. Farber E. Hepatocyte proliferation in stepwise development of experimental liver cell cancer [J]. Dig Dis Sci, 1991； 36（7）∶973.
5. Edmondson HA,Steiner PE. Primary carcinoma of liver. A study of 100 cases among 48 900 necropsies [J]. Cancer, 1954； 7∶462.
6. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis [J]. Am J Clin Pathol, 1995； 103(3)∶300.
7. Soini Y, Virkajarvi N, Lehto VP, et al. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival [J]. Br J Cancer, 1996； 73（9）∶1025.
8. Bravo R, Frank R, Blundell PA, et al.Cyclin/PCNA is the auxiliary protein of DNA polymerasedelta [J]. Nature, 1987； 326(6112)∶515.
9. 阮幼冰，武忠弼，楊木蘭，等. 大鼠肝癌發(fā)生過程中增殖細(xì)胞核抗原及表達(dá) [J]. 中華病理學(xué)雜志，1996； 25（1）∶39.
10. Hino N, Higashi T, Nouso K, et al. Proliferating cell nuclear antigen and grade of malignancy in small hepatocellular carcinomaevaluation in USguided specimens [J]. Hepatogastroenterology, 1997； 44(13)∶245.
11. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation [J]. Am J Pathol,1998； 152(1)∶43.
12. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997； 3(8)∶917.
13. Tamm I, Wang Y, Sausville E, et al.IAPfamily protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs [J]. Cancer Res, 1998； 58(23)∶5315.
14. Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma [J]. Gut, 2000； 46(5)∶645.
15. Monzo M, Rosell R, Felip E, et al. A novel antiapoptosis gene: Reexpression of survivin messenger RNA as a prognosis marker in nonsmallcell lung cancer [J]. J Clin Oncol, 1999； 17(7)∶2100.
16. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma [J]. Oncogene, 2000； 19(5)∶617.
17. Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with CDK4 to resist Fasmediated cell death [J]. Oncogene, 2000； 19(10)∶1346.
18. Ishida M, Gomyo Y, Tatebe S, et al. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferasemediated dUTPbiotin nick end labelling [J]. Virchows Arch, 1996； 428(4-5)∶229.
19. Shin S, Sung BJ, Cho YS, et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase3 and 7 [J]. Biochemistry, 2001; 40(4)∶1117.
20. Ito Y, Matsuura N, Sakon M, et al. Both cell proliferation and apoptosis significantly predict shortened diseasefree survival in hepatocellular carcinoma [J]. Br J Cancer, 1999； 81(4)∶747.
  1. 1. 李連第，張思維，魯鳳珠，等. 中國惡性腫瘤死亡譜及分類構(gòu)成研究 [J]. 中華腫瘤雜志， 1997； 19（5）∶323.
  2. 2. GraslKraupp B, RuttkayNedecky B, Mullauer L, et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression [J]. Hepatology， 1997； 25(4)∶906.
  3. 3. Terada T, Nakanuma Y. Expression of apoptosis, proliferation cell nuclear antigen, and apoptosisrelated antigen (bcl2, cmyc, Fas, Lewisy, and p53) in human cholangiocarcinomas and hepatocellular carcinomas [J]. Pathol Int，1996； 46(10)∶764.
  4. 4. Farber E. Hepatocyte proliferation in stepwise development of experimental liver cell cancer [J]. Dig Dis Sci, 1991； 36（7）∶973.
  5. 5. Edmondson HA,Steiner PE. Primary carcinoma of liver. A study of 100 cases among 48 900 necropsies [J]. Cancer, 1954； 7∶462.
  6. 6. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis [J]. Am J Clin Pathol, 1995； 103(3)∶300.
  7. 7. Soini Y, Virkajarvi N, Lehto VP, et al. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival [J]. Br J Cancer, 1996； 73（9）∶1025.
  8. 8. Bravo R, Frank R, Blundell PA, et al.Cyclin/PCNA is the auxiliary protein of DNA polymerasedelta [J]. Nature, 1987； 326(6112)∶515.
  9. 9. 阮幼冰，武忠弼，楊木蘭，等. 大鼠肝癌發(fā)生過程中增殖細(xì)胞核抗原及表達(dá) [J]. 中華病理學(xué)雜志，1996； 25（1）∶39.
  10. 10. Hino N, Higashi T, Nouso K, et al. Proliferating cell nuclear antigen and grade of malignancy in small hepatocellular carcinomaevaluation in USguided specimens [J]. Hepatogastroenterology, 1997； 44(13)∶245.
  11. 11. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation [J]. Am J Pathol,1998； 152(1)∶43.
  12. 12. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997； 3(8)∶917.
  13. 13. Tamm I, Wang Y, Sausville E, et al.IAPfamily protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs [J]. Cancer Res, 1998； 58(23)∶5315.
  14. 14. Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma [J]. Gut, 2000； 46(5)∶645.
  15. 15. Monzo M, Rosell R, Felip E, et al. A novel antiapoptosis gene: Reexpression of survivin messenger RNA as a prognosis marker in nonsmallcell lung cancer [J]. J Clin Oncol, 1999； 17(7)∶2100.
  16. 16. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma [J]. Oncogene, 2000； 19(5)∶617.
  17. 17. Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with CDK4 to resist Fasmediated cell death [J]. Oncogene, 2000； 19(10)∶1346.
  18. 18. Ishida M, Gomyo Y, Tatebe S, et al. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferasemediated dUTPbiotin nick end labelling [J]. Virchows Arch, 1996； 428(4-5)∶229.
  19. 19. Shin S, Sung BJ, Cho YS, et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase3 and 7 [J]. Biochemistry, 2001; 40(4)∶1117.
  20. 20. Ito Y, Matsuura N, Sakon M, et al. Both cell proliferation and apoptosis significantly predict shortened diseasefree survival in hepatocellular carcinoma [J]. Br J Cancer, 1999； 81(4)∶747.